Review maps evidence gaps in kratom-related polypharmacy deaths

Why it matters

Finding kratom alongside other drugs after a death does not establish how much each substance contributed. A new scoping review examines why current toxicology and interaction evidence often cannot resolve that question.

The big picture

Ella Matischak and Lyle Burgoon reviewed literature identified through April 2026 using PubMed searches, citation tracking and selected government material. This is an evidence map, not a new clinical trial or a pooled estimate of deaths caused by kratom. The authors did not adjudicate individual deaths.

Key findings

• The review used 14 PubMed search queries and included case reports, surveillance analyses and pharmacological research; it did not perform a meta-analysis.
• Other substances were commonly detected in the fatality datasets examined, but co-detection alone could not establish kratom’s causal contribution.
• The authors discuss overlapping opioid-receptor effects and inhibition of drug-metabolizing enzymes as possible pathways for harm, rather than proof of an interaction causing an individual death.
• Missing validated human lethal-concentration reference ranges, postmortem redistribution and instability of 7-OH in stored specimens complicate forensic interpretation.
• The review calls for surveillance that separates botanical leaf, conventional extracts and concentrated or semisynthetic derivatives; comparative polypharmacy fatality risk remains unestablished.

What they say

“The evidence is not yet sufficient to answer causal questions focused on kratom polypharmacy,” Matischak and Burgoon conclude.

Bottom line

The review identifies plausible interaction risks and major forensic gaps, while leaving kratom’s contribution to individual mixed-drug deaths unresolved.